Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50749
Name peripheral T-cell lymphoma
Definition A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Belinostat peripheral T-cell lymphoma not applicable detail...
Unknown unknown Chidamide peripheral T-cell lymphoma not applicable detail...
Unknown unknown Copanlisib peripheral T-cell lymphoma not applicable detail...
Unknown unknown Fenretinide peripheral T-cell lymphoma not applicable detail...
Unknown unknown Duvelisib peripheral T-cell lymphoma not applicable detail...
Unknown unknown Tenalisib peripheral T-cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01431209 Phase II Ruxolitinib Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01644253 Phase I Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab Phase 1b Safety and Efficacy Study of TRU-016 Active, not recruiting USA 0
NCT02181218 Phase I Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Completed USA 0
NCT02232516 Phase II Lenalidomide + Romidepsin Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting USA 0
NCT02273739 Phase Ib/II Enasidenib Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed USA 1
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02464228 Phase II Tipifarnib Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Active, not recruiting USA 2
NCT02495415 Phase II Fenretinide Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Recruiting USA 0
NCT02512497 Phase I Romidepsin Busulfan + Fludarabine + Romidepsin Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Recruiting USA 0
NCT02520791 Phase I MEDI-570 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Recruiting USA | CAN 0
NCT02535247 Phase II Pembrolizumab Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02567656 Phase I Tenalisib Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Completed USA 0
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting USA 5
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Active, not recruiting USA | CAN 4
NCT02689453 Phase I Alemtuzumab + rhIL-15 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Active, not recruiting USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting USA 0
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn USA 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting USA 0
NCT03011814 Phase Ib/II Durvalumab Durvalumab + Lenalidomide Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Recruiting USA 0
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting USA 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting USA 0
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Terminated USA 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03161223 Phase Ib/II Durvalumab + Romidepsin Azacitidine + Durvalumab Azacitidine + Durvalumab + Romidepsin Durvalumab + Pralatrexate + Romidepsin Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Recruiting USA 2
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Recruiting USA 0
NCT03240211 Phase I Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Recruiting USA 2
NCT03264131 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma Recruiting USA 0
NCT03278782 Phase Ib/II Romidepsin Pembrolizumab + Romidepsin Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Recruiting USA 0
NCT03328104 Phase I Cyclophosphamide + Etoposide + Everolimus + Nelarabine Aflac LL1602 ENCERT Recruiting USA 0
NCT03372057 Phase II Duvelisib A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) Recruiting USA 3
NCT03409432 Phase II Brentuximab vedotin + Lenalidomide Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA 3
NCT03534180 Phase II Venetoclax Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma Recruiting USA 0
NCT03547700 Phase Ib/II Ixazomib + Romidepsin Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) Active, not recruiting USA 0
NCT03586999 Phase Ib/II Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Recruiting USA 0
NCT03598998 Phase Ib/II Pembrolizumab + Pralatrexate Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas Recruiting USA 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03719105 Phase I Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Recruiting USA 0
NCT03829540 Phase I CD4CAR CD4CAR for CD4+ Leukemia and Lymphoma Recruiting USA 0
NCT03902184 Phase II Gemcitabine + Lacutamab + Oxaliplatin Lacutamab IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) Recruiting USA 5
NCT03905135 Phase I Avelumab + rhIL-15 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Recruiting USA 0
NCT03921879 Phase I OT-82 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03927105 Phase II Cabiralizumab + Nivolumab Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma Active, not recruiting USA 0
NCT03947255 Phase II Brentuximab vedotin A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Recruiting USA 0
NCT04074746 Phase I Cyclophosphamide + Fludarabine AFM13 Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Recruiting USA 0
NCT04083495 Phase II ATLCAR.CD30 cells CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Recruiting USA 0
NCT04101331 Phase II AFM13 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) Recruiting USA 9
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Recruiting USA 0
NCT04217317 Phase II Bendamustine + CPI-613 CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT04234048 Phase I Fenretinide Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Recruiting USA 4
NCT04464798 Phase I Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas Not yet recruiting USA 3
NCT04639843 Phase I Azacitidine + Doxorubicin + Duvelisib + Romidepsin Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Not yet recruiting USA 0
NCT04747236 Phase II Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting USA 0
NCT04774068 Phase I Romidepsin Parsaclisib + Romidepsin Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Not yet recruiting USA 0